Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of allopurinol to prevent GFR loss in type 1 diabetes
2012-001348-24Phase 3Terminated
- Sponsor
- Joslin Diabetes Center
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of allopurinol in diabetes mellitus type 1 (T1D) and diabetic glomerulosclerosis, sponsored by Joslin Diabetes Center. Primary endpoint: Change in measured GFR (iohexol plasma clearance). Started Sep 2012; status: terminated.
02
Drugs
allopurinol
03
Conditions
diabetes mellitus type 1 (T1D)diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2012-001348-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001348-24.